Senior Manager/Associate Director, Commercial Supply Planning

The Senior Manager/Associate Director, Commercial Supply Planning, will be responsible for leading end-to-end supply planning and S&OP execution across ’s global supply chain. This role will drive alignment between demand, supply, inventory and financial planning to ensure continuous commercial supply.

Responsibilities:

This role will lead commercial supply planning at , which includes the management of monthly S&OP meetings, translation of demand forecasts into supply plans, ensuring supply plans are in alignment with budget, management of inventory to desired safety stock levels, issuance of purchase orders and production forecasts to suppliers, scenario planning to enable supply decisions, and support of business process improvements.

Competencies:

• Leadership and interpersonal skills, including a collaborative and team-oriented approach.
• Excellent verbal and written communication skills, detail-oriented personality, and ability to work and drive change across functions.
• Good organizational, time management and computer and software skills.
• Flexible, able to learn and implement new techniques, technologies, and novel approaches.
• Ability to quickly react to and mitigate unforeseen challenges.
• Ability to build strong relationships with co-workers of various backgrounds and expertise.
• Ability to function at a high level in a team setting whether leading the group or acting as an individual contributor.

Experience:

• Bachelor’s degree; MBA or other advanced degree focused on Supply Chain Management and/or APICS Certified Supply Chain Professional certification is a plus.
• 8 years’ experience in the pharmaceutical industry with at least 5 years’ work experience in a commercial supply setting preferably in international markets.
• Strong experience in end-to-end supply chain processes, including S&OP, supply planning, procurement execution and product launch support
• Strong planning and coordination skills across supply, production, inventory, and external partner activities.
• Knowledge of GMP and global regulatory requirements
• Experience with ERP and planning systems (e.g., SAP, NetSuite, or similar platforms).
• Strong quality and compliance background
• Work history in a virtual or semi-virtual pharmaceutical company.

is an Equal-Opportunity Employer.

is committed to fair and equitable compensation practices, and we strive to provide employees with total compensation packages that are competitive. For this role, the anticipated base pay range is $150,000 - $190,000 DOE. The exact base pay offered for this role will depend on various factors, including but not limited to the candidate’s geography, qualifications, skills, and experience.

The successful candidate will be eligible for an annual performance incentive bonus and a new hire equity package. also offers various benefits offerings, including, but not limited to, medical, dental, vision insurance, 401(k) match, PTO, and paid holidays.

Notice to Recruiters/Staffing Agencies

Recruiters and staffing agencies should not contact through this page. All recruitment vendors (search firms, recruitment agencies, and staffing companies) are prohibited from contacting our hiring manager(s), executive team members, or employees directly.

We require that all recruiters and staffing agencies have a fully executed, formal written agreement on file. ’s receipt or acceptance of an unsolicited resume submitted by a vendor organization to this website or employee does not constitute an actual or implied contract between and such organization and will be considered unsolicited. will not be responsible for related fees.

About Us:

is a commercial biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's first FDA-approved product is REVTORPYK (gedatolisib), a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PAM pathway. REVTORPYK is approved to treat adults with HR+/HER2- advanced breast cancer that progressed on prior endocrine therapy in the metastatic setting.

The Phase 3 VIKTORIA-2 trial is evaluating gedatolisib in combination with palbociclib and either fulvestrant or letrozole for the first-line treatment of HR+/HER2- locally advanced or metastatic breast cancer. A Phase 1/2 clinical trial evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing.